GLYCOPHARM
The Sugar Code: from (bio)chemical concept to clinics
| Coordinatore | AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Totale costo | 3˙005˙458 € |
| EC contributo | 3˙005˙458 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2016-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
ES (MADRID) | coordinator | 1˙047˙070.94 |
| 2 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address
address: BELFIELD contact info |
IE (DUBLIN) | participant | 435˙025.91 |
| 3 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 235˙268.88 |
| 4 |
UNIVERSITAETSKLINIKUM HEIDELBERG
Organization address
address: IM NEUENHEIMER FELD 672 contact info |
DE (HEIDELBERG) | participant | 235˙268.88 |
| 5 |
UNIVERSIDADE DO MINHO
Organization address
address: Largo do Paco contact info |
PT (BRAGA) | participant | 219˙681.00 |
| 6 |
UNIVERZITA KARLOVA V PRAZE
Organization address
address: Ovocny trh 5 contact info |
CZ (PRAHA 1) | participant | 218˙408.52 |
| 7 |
TOSCANA BIOMARKERS S.R.L
Organization address
address: VIA FIORENTINA 1 contact info |
IT (SIENA) | participant | 187˙062.70 |
| 8 |
ROCHE DIAGNOSTICS GMBH
Organization address
address: Sandhofer Strasse 116 contact info |
DE (MANNHEIM) | participant | 172˙200.60 |
| 9 |
INSTITUTE OF APPLIED BIOTECHNOLOGIES AS
Organization address
address: Tymianova 619/14 contact info |
CZ (PRAHA) | participant | 158˙849.91 |
| 10 |
FUNDACION UNIVERSITARIA SAN PABLO-CEU
Organization address
address: ISAAC PERAL 58 contact info |
ES (MADRID) | participant | 96˙620.96 |
| 11 |
ISOSEP AKTIEBOLAG
Organization address
address: DALKARRSVAGEN 11 contact info |
SE (TULLINGE) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Coding of biochemical information is commonly described to be based solely on nucleotides and amino acids, whereas carbohydrates, the most abundant type of molecule in Nature, appear sidelined in this respect. That carbohydrates, as part of cellular glycoconjugates, have exceptional talents for building biochemical signals is an emerging insight, at the heart of the concept of the Sugar Code. Intuitively, emergence of recognition partners for information transfer is expected, and this is the case. Thus, coding of bioinformation in glycans and information transfer via lectins is key to a wealth of medically relevant processes, e.g. infection, immune regulation and malignancy, now awaiting its full exploitation pharmaceutically. To do so, training in this exceptionally interdisciplinary field needs to be provided. With this aim, scientific and country/gender issues are strategically combined in this network. Its composition assures a continuous chain of research expertise, from computational and synthetic chemistry to state of the art biophysical chemistry and structural biology, then to biochemistry, molecular cell biology and pharmaceutical/biomedical sciences, generating innovative clinical approaches. Notably, academia is linked with industry, bringing in the essence of business acumen into the training programme. This activity and the research deliberately planned as interdisciplinary projects ensure an optimal training for young researchers in a dynamically developing area of conspicuous biopharmaceutical potential. Equally important, it lays the foundation to inspire novel strategies for the design of potent and selective inhibitors against lectins and the development of lectins (or suitably engineered variant(s)) as therapeuticals. As a boon for the success of the network, cooperations between several partners have already proven successful, especially increasing the core in Madrid and partners in Dublin, Munich and Prague.'